The sGC activator runcaciguat is associated with a strong reduction in albuminuria and good tolerability in CKD patients with or without an SGLT2 inhibitor. Results of the CONCORD study

Supporters

Support the authors with ResearchCoin

Tip RSC

Topics

Medicine

Internal Medicine

Endocrinology, Diabetes And Metabolism

Cardiology And Cardiovascular Medicine

Receptor

Show all topics

DOI

10.14293/cgmp.24000004.v1

License

CC-BY

Other Formats

PDF